STUDY OF PROPERTIES OF SERUM NEUTRALIZING HIV-INFECTED PATIENTS WITH NON-PROGRESSORS DISEASES OF HIV ISOLATES OF DIFFERENT GENETIC VARIANTS
https://doi.org/10.22328/2077-9828-2015-7-1-45-51
Abstract
In connection with the existing problems in developing a vaccine, which causes time between antibodies against various strains of HIV-1, there is need to develop methods to assess virus neutralization, as well as search for broadly neutralizing antibodies capable of blocking various HIV-1 strains. We investigated the serum of HIV-infected people with non-progressive form of the disease. In our work we used serum subtype A and CRF63_02A1, and the panel of infectious HIV-1 isolates isolated from recently infected patients different genetic and biological characteristics. Reactions were carried out neutralization between homo- and heterologous pairs serum HIV-1 isolate. Analysis showed weaker suppression isolates CRF63_02A1 recombinant form of HIV-1, while sera from individuals infected CRF63_02A1, the vast majority of the studied isolates us, including the homologous HIV-1 isolates.
About the Authors
N. A. Blednyh
State Research Center of Virology and Biotechnology «Vector»
Russian Federation
Russian Federation
N. V. Unagaeva
State Research Center of Virology and Biotechnology «Vector»
Russian Federation
Russian Federation
Y. V. Nikonorova
State Research Center of Virology and Biotechnology «Vector»
Russian Federation
Russian Federation
F. O. Mirdzhamalova
Center for Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
N. Y. Chernousova
Center for Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
S. R. Sauhat
Federal State Institution of Science Rostov Research Institute of Microbiology and Parasitology of Rospotrebnadzor
Russian Federation
Russian Federation
N. M. Gashnikova
State Research Center of Virology and Biotechnology «Vector»
Russian Federation
Russian Federation
References
1. Li Y., Svehla K., Louder M.K. Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals // J. Virol.,- Jan. 2009. - Vol. 83. - Р. 1045-1059.
2. Liao H., Lynch R., Zhou T., Gao F., Alam S.M., Boyd S.D., Fire A.Z., Roskin K.M., Schramm C.A., Zhang Z. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus // Nature. - Apr. 2013. - Р. 469-476.
3. Mikell I., Sather D.N., Kalams S.A., Altfeld M., Alter G., Stamatatos L. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 // PLoS Pathog. - Jan. 2011. - Vol. 7. - Р. 1-15.
4. Walker L.M., Phogat S.K., Chan-Hui P.Y. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target // Science. - Oct. 2009. - Vol. 326. - Р. 285-288.
5. Walker L.M., Huber M., Doores K.J. Broad neutralization coverage of HIV by multiple highly potent antibodies // Nature. - Sept. 2011. - Vol. 477. - Р. 466-470.
6. Abraham R.J., Abrahams F., Tongo M. Refined Identification of Neutralization-Resistant HIV-1 CRF02_AG Viruses // J. of Virol. - July 2012. - Vol. 86. - Р. 7699-7703.
7. Andrabi R., Williams C., Wangb X.-H. Cross-neutralizing activity of human anti-V3monoclonal antibodies derived from non-B clade HIV-1 infected individuals // J. of Virol. - May 2013. - Vol. 439. - P. 81-88.
8. Doria-Rose N.A., Klein R.M., Manion M.M. Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies // J.Virol.,- Jan. 2009. - Vol. 83. - Р. 188-199.
9. Melissa D. Simek M.D., Rida W., Priddy F.H., Pham P., Carrow E., Läufer D.S., Lehrman J.K. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm // J. Virol. - July 2009. - Vol. 83. - Р. 7337-7348.
10. Seaman M. S., Janes H., Hawkins N. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies // J. Virol. - Feb. 2010. - Vol. 84. - Р. 1439-1452.
11. Chun T.W., Mirray D., Justement J.S. Blazkova J., Claire W. Hallahan D. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir // PNAS - July 2014. - Vol. 111. - Р. 1073-1079.
12. Gils M.J., Sanders R.W. In vivo protection by broadly neutralizing HIV antibodies // Trends in Microbiology, Oct. 2014. - Vol. 22. - P. 550-551.
13. Chaillon A., Braibant M., Hue S. et al. Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection // PLoS. - Aug. 2012. - Vol. 7. - P. 1-13.
14. Гашникова Н.М., Сафронов П.Ф., Никонорова Ю.В., Унагаева Н.В., Лаптева Т.А., Богачев В.В. Изучение свойств изолятов CRF02_AG ВИЧ-1, циркулирующих на территории Новосибирской области // Журн. микробиологии, эпидемиологии и иммунобиологии. - 2011. - № 3. - С. 38-43.
15. Baryshev P.B., Bogachev V.V., Gashnikova N.M. Genetic characterization of HIV-1 strains recombinant form AG circulating in Siberia, Russia // Archives of Virol. - Aug. 2012. - Vol. 157. - P. 2335-2341.
16. Peeters M., Liegeois F., Torimiro N., Bourgeois A., Mpoudi E. Characterization of a Highly Replicative Intergroup M/O Human Immunodeficiency Virus Type 1 Recombinant Isolated from a Cameroonian Patient // J. of Virol. - Sept. 1999. - Vol. 73. - Р. 7368-7375.
Review
For citations:
Blednyh N.A., Unagaeva N.V., Nikonorova Y.V., Mirdzhamalova F.O., Chernousova N.Y., Sauhat S.R., Gashnikova N.M. STUDY OF PROPERTIES OF SERUM NEUTRALIZING HIV-INFECTED PATIENTS WITH NON-PROGRESSORS DISEASES OF HIV ISOLATES OF DIFFERENT GENETIC VARIANTS. HIV Infection and Immunosuppressive Disorders. 2015;7(1):45-51. (In Russ.) https://doi.org/10.22328/2077-9828-2015-7-1-45-51
Views:
588
.png)
Email this article 